UK Rapid Test Consortium

From Wikipedia, the free encyclopedia

The UK Rapid Test Consortium (UK-RTC) is a United Kingdom industry consortium created to produce a lateral flow rapid test for COVID-19. Rapid tests are a form of COVID-19 testing technology that was originally developed from significant investment by the United Kingdom government to develop new forms of COVID-19 testing that provided advantages over existing forms such as PCR. Its members include Abingdon Health, , CIGA Healthcare, , and Oxford University.[1][2]

In 2020, the consortium developed the AbC-19 rapid test to meet UK government requirements for a rapid testing solution.[2] The government ordered 1 million of the UK-RTC's rapid tests in October 2020.[3]

Distribution[]

CIGA Healthcare will be responsible for assembly and distribution, and has also been awarded distribution to the US after recent FDA approval.[4]

References[]

  1. ^ "rapidmicrobiology UK Begin At-Home COVID-19 Antibody Testing Programme". www.rapidmicrobiology.com. Retrieved 2020-11-13.
  2. ^ a b "Industry responds to call to arms to build British diagnostics industry at scale". GOV.UK. Retrieved 2020-11-13.
  3. ^ "Government invests in UK-developed antibody tests from UK Rapid Test Consortium". GOV.UK. Retrieved 2020-11-13.
  4. ^ "Yorkshire developed Covid-19 test approved for use in North America".
Stub icon

This article about the COVID-19 pandemic is a stub. You can help Wikipedia by .

  • v
  • t
Stub icon

This article about a UK medical organisation, hospital, or association is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""